Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2016 · 10-Q
Revenue$4.05M$4.05M+24.2% vs Q2 2015 Net Income-$1.76M-$1.76MN/M vs Q2 2015 EPS Diluted-$0.54-$0.54N/M vs Q2 2015 Gross Profit$2,090,000+20.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,748,000N/M Free Cash Flowderived-$1,829,000N/M Margins · derivedGross margin51.6%−1.5 pt vs Q2 2015
Operating margin-45.8%+1.5 pt vs Q2 2015
Net margin-43.5%−21.5 pt vs Q2 2015
ended Sep 30, 2015 · filed Nov 10, 2015 · 41 d after period end